![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Panitumumab is a fully human monoclonal IgG2 antibody targeting the EGF receptor (EGFR). This agent represents a new class of drug owing to its fully human nature, and no need for premedication and loading dose. Panitumumab selectively binds to EGFR, blocking the extracellular domain of the receptor, and has not been associated with the formation of any antibodies directed against it. The drug is indicated as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. The safety profile is favorable and is generally well tolerated; the most common toxicities are skin rashes and diarrhea. Therefore, panitumumab’s hypersensitivity reaction rate is lower when compared with a chimeric monoclonal antibody such as cetuximab. Panitumumab increases the clinician’s repertoire of agents to treat metastatic colorectal carcinoma. The available clinical data are the most promising for a single-agent anti-EGFR monoclonal antibody in this disease at the present time. These new data open different clinical scenarios in metastatic colorectal carcinoma patients and encourage clinicians and basic researchers to investigate new therapeutic approaches for this patient subset.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.